Vaccine tests in immunocompromised hosts should be encouraged to assess antibody assays associated with clinical protection as well as indirect measures such as functional and complete type-specific antibody levels

Vaccine tests in immunocompromised hosts should be encouraged to assess antibody assays associated with clinical protection as well as indirect measures such as functional and complete type-specific antibody levels. using both functional antibody assays and standard ELISA antibody titers. (ClinicalTrials.gov:NCT00307125)